Safety, Antibody Response After Doses of Pfizer-BioNTech Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 14, 2021

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.26344?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091421

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

What The Study Did: Researchers document the antibody response to a second dose of Pfizer-BioNTech (BNT162b2) vaccine in a group of 117 allogeneic hematopoietic (from a donor) stem cell transplant recipients.

Authors: Patrice Chevallier, M.D., Ph.D., of Nantes University Hospital in Nantes, France, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2021.26344)

Editor’s Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.